Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2021

Kunimasa Kei, Oka Toru, Hara Satoshi, Yamada Noriyuki, Oizumi Satoshi, Miyashita Yoshihiro, Kamada Risa, Funamoto Tomoya, Kawachi Hayato, Kawamura Takahisa, Inoue Takako, Kuhara Hanako, Tamiya Motohiro, Nishino Kazumi, Matsunaga Takashi, Imamura Fumio, Fujita Masashi, Kumagai Toru

Abstract excerpt

INTRODUCTION: The use of osimertinib is associated with the risk of cancer therapy-related cardiac dysfunction (CTRCD) for EGFR-mutated non-small cell lung cancer (NSCLC) patients. In this study, we aimed to clarify the clinical features of patients with CTRCD associated with osimertinib. METHODS: A total of 183 cases of advanced EGFR-mutated NSCLC who received osimertinib monotherapy from January 2014 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Heart Diseases

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33277055
DOI: 10.1016/j.lungcan.2020.10.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.PMID 33277055Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

[A Case of Significant Ejection Fraction Reduction and Heart Failure Induced by Osimertinib].Semantic proximity Read ↗

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read ↗

Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibSemantic proximity Read ↗

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.